Baseline patient characteristics
| Characteristic (N = 28) . | N . | % . |
|---|---|---|
| Age, median (range) | 57 (27, 76) | |
| Patient sex | ||
| Male | 21 | 75 |
| Female | 7 | 25 |
| ECOG performance status | ||
| 0 | 10 | 35.7 |
| 1 | 15 | 53.6 |
| 2 | 3 | 10.7 |
| Primary disease | ||
| AML | 10 | 35.7 |
| MDS | 7 | 25 |
| HL | 5 | 17.9 |
| Non-Hodgkin lymphoma* | 3 | 10.7 |
| Leukemia, NOS | 1 | 3.6 |
| Chronic lymphocytic leukemia | 1 | 3.6 |
| Myeloproliferative disorder† | 1 | 3.6 |
| Disease status at transplant | ||
| 1st CR | 9 | 32.1 |
| 2nd CR | 1 | 3.6 |
| Partial remission | 9 | 32.1 |
| Untreated | 1 | 3.6 |
| Refractory (induction failure) | 5 | 17.9 |
| Relapsed | 3 | 10.7 |
| HLA typing (A, B, C, DRB1, DQB1) | ||
| 8/8 matched | 19 | 67.9 |
| 6/6 matched | 20 | 71.4 |
| Donor type | ||
| Unrelated donor | 13 | 46.4 |
| Matched related donor | 12 | 42.9 |
| Haploidentical donor | 3 | 10.7 |
| Recipient/donor sex | ||
| Male ← Male | 16 | 57.1 |
| Male ← Female | 5 | 17.9 |
| Female ← Male | 4 | 14.3 |
| Female ← Female | 3 | 10.7 |
| Conditioning intensity | ||
| Nonmyeloablative | 22 | 78.6 |
| Myeloablative | 6 | 21.4 |
| Source of progenitor cells | ||
| Peripheral blood stem cells | 22 | 78.6 |
| Bone marrow | 5 | 17.9 |
| Bone marrow and PBSC | 1 | 3.6 |
| Disease status at time of enrollment | ||
| Relapsed | 23 | 82.1 |
| Persistent disease | 5 | 17.9 |
| Prior treatment of disease post–alloHCT | ||
| Yes | 19 | 67.9 |
| No | 9 | 32.1 |
| Prior aGVHD | ||
| Yes (3 grade 1, 6 grade 2) | 9 | 32.1 |
| No | 19 | 67.9 |
| Prior cGVHD | ||
| Yes (3 limited, 1 extensive) | 4 | 14.3 |
| No | 24 | 85.7 |
| Any prior a/c GVHD | ||
| Yes | 12 | 42.9 |
| No | 16 | 57.1 |
| Number of prior treatment regimens (excluding alloHCT), median (range) | 2 (1, 9) | |
| Prior autologous stem cell transplantation, patients (%) | 5 (17.9) | |
| Months from relapse to enrollment, median (range) | 1.1 (0.33, 38.4) | |
| Months from alloHCT to enrollment, median (range) | 21 (5.6, 108.5) | |
| Characteristic (N = 28) . | N . | % . |
|---|---|---|
| Age, median (range) | 57 (27, 76) | |
| Patient sex | ||
| Male | 21 | 75 |
| Female | 7 | 25 |
| ECOG performance status | ||
| 0 | 10 | 35.7 |
| 1 | 15 | 53.6 |
| 2 | 3 | 10.7 |
| Primary disease | ||
| AML | 10 | 35.7 |
| MDS | 7 | 25 |
| HL | 5 | 17.9 |
| Non-Hodgkin lymphoma* | 3 | 10.7 |
| Leukemia, NOS | 1 | 3.6 |
| Chronic lymphocytic leukemia | 1 | 3.6 |
| Myeloproliferative disorder† | 1 | 3.6 |
| Disease status at transplant | ||
| 1st CR | 9 | 32.1 |
| 2nd CR | 1 | 3.6 |
| Partial remission | 9 | 32.1 |
| Untreated | 1 | 3.6 |
| Refractory (induction failure) | 5 | 17.9 |
| Relapsed | 3 | 10.7 |
| HLA typing (A, B, C, DRB1, DQB1) | ||
| 8/8 matched | 19 | 67.9 |
| 6/6 matched | 20 | 71.4 |
| Donor type | ||
| Unrelated donor | 13 | 46.4 |
| Matched related donor | 12 | 42.9 |
| Haploidentical donor | 3 | 10.7 |
| Recipient/donor sex | ||
| Male ← Male | 16 | 57.1 |
| Male ← Female | 5 | 17.9 |
| Female ← Male | 4 | 14.3 |
| Female ← Female | 3 | 10.7 |
| Conditioning intensity | ||
| Nonmyeloablative | 22 | 78.6 |
| Myeloablative | 6 | 21.4 |
| Source of progenitor cells | ||
| Peripheral blood stem cells | 22 | 78.6 |
| Bone marrow | 5 | 17.9 |
| Bone marrow and PBSC | 1 | 3.6 |
| Disease status at time of enrollment | ||
| Relapsed | 23 | 82.1 |
| Persistent disease | 5 | 17.9 |
| Prior treatment of disease post–alloHCT | ||
| Yes | 19 | 67.9 |
| No | 9 | 32.1 |
| Prior aGVHD | ||
| Yes (3 grade 1, 6 grade 2) | 9 | 32.1 |
| No | 19 | 67.9 |
| Prior cGVHD | ||
| Yes (3 limited, 1 extensive) | 4 | 14.3 |
| No | 24 | 85.7 |
| Any prior a/c GVHD | ||
| Yes | 12 | 42.9 |
| No | 16 | 57.1 |
| Number of prior treatment regimens (excluding alloHCT), median (range) | 2 (1, 9) | |
| Prior autologous stem cell transplantation, patients (%) | 5 (17.9) | |
| Months from relapse to enrollment, median (range) | 1.1 (0.33, 38.4) | |
| Months from alloHCT to enrollment, median (range) | 21 (5.6, 108.5) | |